NL-OMON21846RecruitingNot Applicable
PI3K pathway analysis in tumor tissue and circulating DNA to obtain further insight in the efficacy of everolimus when combined with exemestane - A side-study protocol attached to treatment with everolimus and exemestane for postmenopausal patients with hormone receptor-positive advanced metastatic breast cancer, who have progressed on anastrozole or letrozole
VU University Medical Center0 sites175 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 175
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Patients eligible for inclusion in this side-study have to meet all of the following criteria:
- •1.Adult women (> 18 years of age) with metastatic or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy.
Exclusion Criteria
- •Patients eligible for this study must not meet any of the following criteria:
- •1.HER2-overexpressing patients by local laboratory testing (IHC 3+ staining or in situ hybridization positive).
Investigators
Similar Trials
Completed
Not Applicable
PI3K pathway analysis in tumor tissue and circulating DNA to obtain further insight in the efficacy of everolimus when combined with exemestane. A side-study protocol attached to standard treatment with everolimus and exemestane for postmenopausal patients with hormone receptor-positive advanced metastatic breast cancer, who have progressed on anastrozole or letrozoleadvanced metastatic breast cancer10006291breast cancerNL-OMON46855Vrije Universiteit Medisch Centrum175
Active, not recruiting
Phase 1
Analysis of tumor tissue and circulating genetic material in the blood to obtain further insight in the effectiveness of everolimus when combined with exemestane.A side-study protocol attached to standard treatment with everolimus and exemestane for postmenopausal patients with advanced metastatic breast cancer, who have progressed on anastrozole or letrozole.Hormone receptor-positive advanced metastatic breast cancer in postmenopausal patients who have progressed on anastrozole or letrozole.EUCTR2013-004120-11-NLVU University Medical Center175
Completed
Phase 1
Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid TumorsSolid TumorsNCT02439489Fondazione Michelangelo34
Not yet recruiting
Phase 1
Based on PI3K/AKT/HIF-1 signaling pathway, to explore the clinical efficacy and mechanism of Zuoguiyin intervention in oxidative stress in the treatment of premature ovarian insufficiencyPremature ovarian insufficiencyITMCTR2023000069Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine
Unknown
Not Applicable
Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With ExemestaneHormone Receptor Positive Malignant Neoplasm of BreastMetastatic Breast CancerNCT02109913Amsterdam UMC, location VUmc175